KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Total Current Liabilities data on record, last reported at $4.5 billion in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $4.5 billion; the TTM value through Sep 2025 reached $4.5 billion, changed N/A, while the annual FY2024 figure was $3.6 billion, 0.48% changed from the prior year.
  • Total Current Liabilities reached $4.5 billion in Q3 2025 per VRTX's latest filing, up from $4.1 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $4.5 billion in Q3 2025 and bottomed at $1.9 billion in Q3 2021.
  • Average Total Current Liabilities over 5 years is $3.2 billion, with a median of $3.6 billion recorded in 2023.
  • The widest YoY moves for Total Current Liabilities: up 14.09% in 2021, down 4.48% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $2.1 billion in 2021, then grew by 1.78% to $2.2 billion in 2022, then skyrocketed by 62.71% to $3.5 billion in 2023, then increased by 0.48% to $3.6 billion in 2024, then rose by 25.55% to $4.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $4.5 billion in Q3 2025, $4.1 billion in Q2 2025, and $3.8 billion in Q1 2025.